4/17
08:04 am
cldx
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]
Low
Report
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]
4/17
08:01 am
cldx
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Low
Report
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
4/8
11:45 am
cldx
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]
Low
Report
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]
3/22
02:32 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
3/8
07:00 am
cldx
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Low
Report
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
3/5
10:44 am
cldx
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]
3/5
10:30 am
cldx
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Low
Report
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
3/5
10:10 am
cldx
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/29
09:14 pm
cldx
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Medium
Report
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
2/29
01:54 pm
cldx
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
2/29
11:43 am
cldx
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know [Yahoo! Finance]
2/28
04:13 pm
cldx
Celldex Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Celldex Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
2/28
04:01 pm
cldx
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
2/27
12:12 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
2/27
06:40 am
cldx
Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
2/26
07:45 am
cldx
Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/26
07:07 am
cldx
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
07:01 am
cldx
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
High
Report
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2/24
02:13 pm
cldx
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria [Yahoo! Finance]
High
Report
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria [Yahoo! Finance]
2/24
02:05 pm
cldx
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
High
Report
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2/20
08:36 am
cldx
TipRanks'‘Perfect 10' List: These 2 Biotech Stocks Look Compelling at Current Levels [Yahoo! Finance]
Low
Report
TipRanks'‘Perfect 10' List: These 2 Biotech Stocks Look Compelling at Current Levels [Yahoo! Finance]
2/6
04:01 pm
cldx
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Low
Report
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2/5
08:04 am
cldx
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 [Yahoo! Finance]
Medium
Report
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 [Yahoo! Finance]
2/5
08:01 am
cldx
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
Medium
Report
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
1/19
08:04 am
cldx
Despite shrinking by US$130m in the past week, Celldex Therapeutics (NASDAQ:CLDX) shareholders are still up 662% over 5 years [Yahoo! Finance]
Low
Report
Despite shrinking by US$130m in the past week, Celldex Therapeutics (NASDAQ:CLDX) shareholders are still up 662% over 5 years [Yahoo! Finance]